A5068714209- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Vascular Anomalies and Treatments
- Cardiovascular Function and Risk Factors
- Transplantation: Methods and Outcomes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Healthcare and Venom Research
- COVID-19 Clinical Research Studies
- Renin-Angiotensin System Studies
- Medical Imaging and Pathology Studies
- Heart Failure Treatment and Management
- Venomous Animal Envenomation and Studies
- Inflammasome and immune disorders
- Extracellular vesicles in disease
- Entomological Studies and Ecology
- Diverse Scientific Research Studies
Bicêtre Hospital
2023-2024
Assistance Publique – Hôpitaux de Paris
2023-2024
Hypertension pulmonaire : physiopathologie et innovation thérapeutique
2023-2024
University of Calgary
2020-2024
Inserm
2023-2024
Hôpital Marie Lannelongue
2023-2024
Université Paris-Saclay
2023-2024
AR2i
2023
Pulmonary hypertension (PH) refers to a pathologic elevation of the mean pulmonary artery pressure (mPAP) and is associated with increased morbidity mortality in wide range medical conditions. These conditions are classified according similarities pathophysiology management addition their invasive hemodynamic profiles. The 2022 ESC/ERS guidelines for diagnosis treatment present newest clinical classification system includes significant updates definitions. now hemodynamically defined as an...
Russell's viper (Daboia russelii russelii) is an important cause of morbidity and mortality in Sri Lanka. In a study 1985, Haffkine equine polyspecific antivenom doses up to 20 g proved ineffective clearing antigenaemia caused high incidence anaphylactoid reactions. A new, monospecific ovine Fabantivenom (Polonga TAb) has been developed against the venom Lankan and, assess its safety efficacy, we carried out (in 1997) open, randomized comparison this with currently use country. Patients...
Abstract Pulmonary hypertension (PH) is a pathophysiological manifestation of heterogeneous group diseases characterized by abnormally elevated pulmonary arterial pressures diagnosed on right heart catheterization. The 2022 European Society Cardiology (ESC) and Respiratory (ERS) Guidelines for the diagnosis treatment PH provides new hemodynamic definition to define lowering threshold mean artery pressure (mPAP) 20 mm Hg. Precapillary thus now defined as mPAP >20 Hg together with normal...
Abstract Pulmonary arterial hypertension is a severe life-threatening condition associated with increased pulmonary vascular resistance and resulting right heart dysfunction. Admission to intensive care unit acutely decompensated failure significant negative prognostic event high risk of multisystem organ dysfunction death. Presentations are heterogenous may combine signs both diastolic systolic complicating management. Renal often present, but other systems can be involved in findings such...
<b>Rationale:</b> Pulmonary hypertension (PH) has been described in patients treated with proteasome inhibitors (PI). <b>Objectives:</b> To evaluate the association between PI and precapillary PH. <b>Methods:</b> Characteristics of incident PH cases carfilzomib and bortezomib from French Registry VIGIAPATH program 2004 to 2022 were analyzed, concurrently a pharmacovigilance disproportionality analysis using the WHO global database meta-analysis. <b>Results:</b> Eleven...
<b>Background:</b> Improved hemodynamics are typically observed after BPA in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Our aim was to retrospectively compare who had a good hemodynamic response those did not. <b>Methods:</b> Consecutive non-operable CTEPH underwent between November 2015 2020 were included our analysis. Pulmonary vascular resistance (PVR) below three WU considered BPA. Baseline characteristics of achieved this PVR threshold compared not...